glp·helper
glphelper.com/tirzepatide/maryland/baltimore
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Baltimore, MD

Verified Tirzepatide providers in Baltimore, MD. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
33
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Maryland
33 of 33 shown

Find a Tirzepatide provider in Maryland.

Every entry is checked against the NPI registry and the Maryland medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Maryland city · /tirzepatide/maryland/{city}
§ 03Getting Tirzepatide in Baltimore
33 providers · Baltimore, MD

How to get Tirzepatide in Baltimore.

33 GLP-1 prescribers and 7 local resource types are on record for Baltimore, plus 2 nearby towns in the directory.

Prescribers in Baltimore
33 prescribers
33 GLP-1 prescribers in Baltimore, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (14), Family Medicine (10) and Internal Medicine (5). Any Maryland-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Columbia (30 providers) and Rockville (43 providers).
Around the prescription in Baltimore
7 listed nearby
6 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Baltimore.
Medicaid (weight loss)
Diabetes only
As of April 2026, Maryland Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Maryland’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Maryland

Diagnosed diabetes reaches 10.9% of adults in Maryland.

of Maryland adults have obesity
32.7%
diagnosed diabetes
10.9%

Age-adjusted estimates for Maryland, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight losswhat to expect week by week
§ 05Support around Tirzepatide in Baltimore
6 gyms

The prescription is one part. Here is the rest, in Baltimore.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Baltimore, MD, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Planet Fitness
GYM
4.4 on Google · 1428 reviews
5425 Baltimore National Pike
Website
Crunch Fitness - Canton
GYM
4.5 on Google · 991 reviews
3991 Boston St
Website
LA Fitness
GYM
4.0 on Google · 966 reviews
3551 Washington Blvd
Website
Planet Fitness
GYM
4.5 on Google · 945 reviews
6859 Loch Raven Blvd
Website
Planet Fitness
GYM
4.5 on Google · 938 reviews
597 E Ordnance Rd
Website
Planet Fitness
GYM
4.4 on Google · 910 reviews
1401 Merritt Blvd
Website

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Rage Room
REC CENTER
4.4 on Google · 503 reviews
102 Roesler Rd
Website
Merritt Clubs Downtown Athletic Club
FITNESS
4.3 on Google · 492 reviews
210 E Centre St
Website
Exile Fitness
FITNESS
4.7 on Google · 355 reviews
8303 Pulaski Hwy
Website
Merritt Clubs Towson
FITNESS
4.5 on Google · 351 reviews
8757 Mylander Ln
Website
Northeast Regional Recreation Center
REC CENTER
4.2 on Google · 299 reviews
7501 Oakleigh Rd
Website
Retriever Activities Center
REC CENTER
4.4 on Google · 271 reviews
Retriever Activities Center, 1000 Hilltop Cir #201
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Maryland

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Maryland

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]